The Role of 3-O-Methyldopa in the Side Effects of l-dopa
Authors:
- 24 August 2007
- journal article
- research article
- Published by Springer Nature in Neurochemical Research
- Vol. 33 (3) , 401-411
Abstract
Long-term treatment of l-dopa for Parkinson’s disease (PD) patients induces adverse effects, including dyskinesia, on–off and wearing-off symptoms. However, the cause of these side effects has not been established to date. In the present study, therefore, 3-O-methyldopa (3-OMD), which is a major metabolite of l-dopa, was tested to determine whether it plays a role in the aforementioned adverse effects. The effects of 3-OMD on the dopaminergic nervous system in the brain were investigated, by examining behavioral, biochemical, and cellular changes in male Sprague–Dawley rats and catecholamine-producing PC12 neuronal cells. The results revealed that the intracerebroventricular (icv) injection of 1 μmol of 3-OMD impaired locomotor activities by decreasing movement time (MT), total distance (TD), and the number of movement (NM) by 70, 74 and 61%, respectively. The biochemical analysis results showed that a single administration of 1 μmole of 3-OMD decreased the dopamine turnover rate (DOPAC/DA) by 40.0% in the rat striatum. 3-OMD inhibited dopamine transporter and uptake in rat brain striatal membranes and PC12 cells. The subacute administration of 3-OMD (5 days, icv) also significantly impaired the locomotor activities and catecholamine levels. 3-OMD induced cytotoxic effects via oxidative stress and decreased mitochondrial membrane potential in PC12 cells, indicating that 3-OMD can damage neuronal cells. Furthermore, 3-OMD potentiated l-dopa toxicity and these toxic effects induced by both 3-OMD and l-dopa were blocked by vitamin E (α-tocopherol) in PC12 cells, indicating that 3-OMD may increase the toxic effects of l-dopa to some extent by oxidative stress. Therefore, the present study reveals that 3-OMD accumulation from long-term l-dopa treatment may be involved in the adverse effects of l-dopa therapy. Moreover, l-dopa treatment might accelerate the progression of PD, at least in part, by 3-OMD.Keywords
This publication has 49 references indexed in Scilit:
- PLASMA O-METHYLDOPA IN LEVODOPA-INDUCED DYSKINESIAS A Bioclinical InvestigationActa Neurologica Scandinavica, 2009
- Effects of Homocysteine on the Dopaminergic System and Behavior in RodentsNeuroToxicology, 2005
- Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson?s diseaseJournal of Neural Transmission, 2003
- l-Dopa Upregulates the Expression and Activities of Methionine Adenosyl Transferase and Catechol-O-MethyltransferaseExperimental Neurology, 2001
- LEVODOPA AND 3-O-METHYLDOPA IN CEREBROSPINAL FLUID AFTER LEVODOPA-CARBIDOPA ASSOCIATIONPharmacological Research, 1997
- Effect of L-Dopa and the Catechol-O-Methyltransferase Inhibitor Ro 41–0960 on Sulfur Amino Acid Metabolites in RatsClinical Neuropharmacology, 1997
- Intense oxidative DNA damage promoted by l‐DOPA and its metabolites implications for neurodegenerative diseaseFEBS Letters, 1994
- 3-O-Methyldopa Attenuates the Effects of Madopar on the Haloperidol-lnduced Cataleptic Behavior and the Locomotor Activity in the MousePharmacology, 1994
- Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatumLife Sciences, 1984
- 3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatumAnnals of Neurology, 1982